• English
  • 简体中文
Login Register
Current Location: Home > Marketing Drugs(EU) Feedback Help Print
Product No EMEA/H/C/002737
Brand Name Adempas
Nonproprietary Name riociguat
API riociguat
ATC Code C02KX05
Indications Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with inoperable CTEPH, persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity (see section 5.1). Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease (see section 5.1).
Orphan Drug yes
Generics no
Marketing Authorization Holder Bayer Pharma AG
Status Authorised
Authorization Date 2014-03-27
Version 3
Condition Approval no
Exceptions no
Biosimilar no
Details 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息)